Contact Us

Email
helios001@cartesiantx.com

Location
7495 New Horizon Way, Frederick, MD 21703

Pioneering Cell Therapy for Autoimmunity

www.cartesiantherapeutics.com

Descartes-08

Descartes-08 is an investigation product not yet approved by the US Food and Drug Administration (FDA).

Descartes-08 is an autologous T-cell product expressing a chimeric antigen receptor (CAR) directed against B-cell maturation antigen (BCMA) on plasma cells, plasma blasts, and plasmacytoid dendritic cells.

Descartes-08 is a cell therapy that uses mRNA to transiently express the BCMA-directed CAR proteins.

Cartesian therapeutics

helios

Descartes-08 for Children, Adolescents, and Young Adults with Autoimmune Diseases

www.cartesiantherapeutics.com



mRNA Cell Therapy

Cartesian's mRNA approach to CAR-T therapies is designed to expand the reach of potent cell therapy products to address autoimmunity.

No Lymphodepletion
No associated cytopenia or chemotherapy toxicities

Administered Outpatient
Convenient dosing schedule

Delivered at Therapeutic Levels
Designed to deliver dose levels without uncontrolled proliferation

Transient Cell Modification
Does not carry risk of genomic integration

helios
TRIAL

Phase 1/2 dose-escalation basket study evaluating the safety, tolerability, and early efficacy of Descartes-08 in four pediatric indications:

- Juvenile Dermatomyositis (JDM)*
- Childhood-onset Lupus (cSLE)
- ANCA-associated Vasculitis (AAV)
- Juvenile Myasthenia Gravis (JMG)

*JDM has received Rare Pediatric Disease Designation for DC-08

Study Design

Part 1

Intrapatient Dose Level Escalation
DL 1-> DL 2-> DL 3
1x/week inpatient infusions over 6 weeks

Part 2

Maximum Tolerated Dose from Part 1 administered 1x/week over 6 weeks in an outpatient setting

Part 1 – Initial Safety Cohort

- Up to 18 participants
- If a DLT occurs in the first 3 participants, study converts to a 3+3 dose-escalation design

Part 2 – Basket Expansion Phase

- Up to 10 participants per cohort
- Weekly dosing at the MTD established in Part 1

Eligbility Criteria

- **Patients must be at least 12 years of age**
- **Definitive diagnosis for cSLE, AAV, JDM, or JMG**
- **Diagnosis ≥12 months prior to screening required**
- **Must not have weakness sufficient to require wheelchair**
- **No history or presence of active CNS lupus or other CNS disease**
- **Concomitant immunosuppressive drugs must be deemed necessary by the investigator**

To learn more about the full eligibility criteria for the study, please contact us by email helios001@cartesiantx.com